BRIGATINIB clinical trials

ETOP 21-21 BOUNCE: A multicentre, randomised, phase II trial of brigatinib consolidation versus observation or durvalumab in patients with unresectable stage III NSCLC and ALK-rearrangement, after definitive chemo-radiotherapy.

This study is for people with a type of lung cancer called NSCLC with a specific gene change (ALK-rearrangement). It's looking at whether a drug called Brigatinib, given after chemotherapy and radiation, can stop the cancer from growing for longer compared to other treatments or no further treatment.